Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-38

All in all I like this news

In theory Starpharma raised a proxy of $38 million to fund development of novel drugs

Nothing wrong with that

Just another avenue to help commercialise products

Cheryl Maley, CEO of Starpharma, commented
This is just one of many ongoing efforts to prioritise the commercialisation of Starpharma’s DEP® platform and our partnerships to advance the application of the DEP® technology in high value novel therapeutic areas


My interpretation of M/S partnership announcement today is for development of new drugs that are in preclinical studies

Radiotheranostics
ADC's
etc

Shyam Masrani, Principal at Medicxi and Board representative of Petalion, commented: “While the field of targeted conjugates has experienced remarkable growth and led to the approval of several treatment options for patients with cancer, it is also evident that the current approaches have limitations. Medicxi is excited to support Petalion under the leadership of Dr Shahidi from the outset and we look forward to working closely with the Starpharma team to develop a highly differentiated and effective new medicine.”




As far as the Phase 2 in house Dep products........this has nothing to do with this agreement

Questions for the Webinar

Equity of 22.5% in Petalian

Is there an option to increase holding in entity. I figure a further 22.5% will bring stake to a maximum of 45% with the controlling interest being held by Medixi

Will the focus be on preclinical drugs currently being studied in Starpharma's labs